Completed

Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity

Lead sponsor

Göteborg University

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

128

Study population

Obesity / overweight

Eligibility highlights

Primary endpoint

•BMI SDS, change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07304141

Org study IDDnr 2023-04013-01

Timeline

Milestones

Study start2023-12-20actual

Primary completion2025-12-12actual

Study completion2025-12-12actual

Study first posted2025-12-26actual

Last update posted2026-02-27actual

Assets

Investigational agents

Liraglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age10 Years

Maximum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Children at the Pediatric Clinic, Region Halland, and at the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital.

Inclusion criteria

•Adolescents aged 10-18 years with obesity who were offered pharmacological treatment

•Provided consent to participate

•Participants with short treatment duration, early adverse effects, or who proceeded to surgery are also included in baseline data

Exclusion criteria

•Hypothalamic obesity

•Craniopharyngioma

•Syndromic obesity / monogenic obesity

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint

Primary/protocol endpoint

Change in Body Mass Index Standard Deviation Score (BMI SDS) over time

Time frame:The primary outcome, change in BMI SDS, will be evaluated at -12 months (pre-baseline), at baseline (0 months), and at +3-6, +12, and +18 months following treatment initiation.

BMI SDS, change

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.